Serum microRNAs as biomarkers for recurrence in melanoma

Erica B Friedman1,2, Shulian Shang3, Eleazar Vega-Saenz de Miera1,4, Jacob Ulrik Fog5, Maria Wrang Teilum5, Michelle W Ma1,4, Russell S Berman1,2, Richard L Shapiro1,2, Anna C Pavlick1,4,6, Eva Hernando1,7, Adam Baker5, Yongzhao Shao1,3 and Iman Osman1,4*

Abstract

Background: Identification of melanoma patients at high risk for recurrence and monitoring for recurrence are critical for informed management decisions. We hypothesized that serum microRNAs (miRNAs) could provide prognostic information at the time of diagnosis unaccounted for by the current staging system and could be useful in detecting recurrence after resection.

Methods: We screened 355 miRNAs in sera from 80 melanoma patients at primary diagnosis (discovery cohort) using a unique quantitative reverse transcription-PCR (qRT-PCR) panel. Cox proportional hazard models and Kaplan-Meier recurrence-free survival (RFS) curves were used to identify a miRNA signature with prognostic potential adjusting for stage. We then tested the miRNA signature in an independent cohort of 50 primary melanoma patients (validation cohort). Logistic regression analysis was performed to determine if the miRNA signature can determine risk of recurrence in both cohorts. Selected miRNAs were measured longitudinally in subsets of patients pre-/post-operatively and pre-/post-recurrence.

Results: A signature of 5 miRNAs successfully classified melanoma patients into high and low recurrence risk groups with significant separation of RFS in both discovery and validation cohorts (p = 0.0036, p = 0.0093, respectively). Significant separation of RFS was maintained when a logistic model containing the same signature set was used to predict recurrence risk in both discovery and validation cohorts (p < 0.0001, p = 0.033, respectively). Longitudinal expression of 4 miRNAs in a subset of patients was dynamic, suggesting miRNAs can be associated with tumor burden.

Conclusion: Our data demonstrate that serum miRNAs can improve accuracy in identifying primary melanoma patients with high recurrence risk and in monitoring melanoma tumor burden over time.

Keywords: Melanoma, Serum microRNA, Prognostic biomarkers, Recurrence, Surveillance

Background

Melanoma remains a highly morbid disease in the United States, and its incidence has continued to rise over the past few decades [1]. The toll in terms of “life-years lost” in melanoma is the highest of all solid tumors in the United States [2]. Recurrence risk varies by stage, with estimated recurrence rates of up to 30% for localized melanoma and 60% for regional nodal disease [3]. Both the identification of patients at high risk for recurrence at primary diagnosis and the early detection of disease relapse are critical for informed management decisions.

The current standard of care for determining the prognosis of melanoma patients with localized disease and guiding post-operative follow-up both have limitations. In using prognostic factors, such as primary tumor thickness, ulceration, mitotic rate, and lymph node involvement, the American Joint Committee on Cancer (AJCC) staging system is able to provide first-line stratification for melanoma-specific survival [4]. However, the
current staging system only partly explains the variability in the prognosis of melanoma, and there remains unexplained heterogeneity within each stage. Additionally, despite the benefit of early detection of locoregional and distant metastases amenable to curative resection [3,5], there is no consensus on either the selection or timing of imaging studies and laboratory tests for use in follow-up [6]. This is in part due to the limited sensitivity and specificity of available imaging modalities and blood tests, coupled with considerable economic cost [7].

Due to the routine collection and facility of obtaining blood samples at multiple time points, blood-based biomarkers are a logical and cost effective source in the search for non-invasive biomarkers. Although assessment of circulating markers for prognosis and surveillance has been part of the standard of care in breast and colon cancer management for several years [8], no such markers exist for early-stage melanoma. While many molecules have been studied as biomarkers for use in melanoma [9-11], none have been developed into a clinically relevant assay. Currently, serum lactate dehydrogenase is the only blood-based marker routinely used in melanoma, but it has only shown prognostic significance in advanced disease [4,10,11] and is rarely the sole indicator of recurrence [12]. There remains a need to develop methods to accurately determine recurrence risk of primary melanoma patients and improve follow-up for early detection of relapse.

MicroRNAs (miRNAs) are small, non-coding RNAs that negatively regulate gene expression at the post-transcriptional level [13]. Given their implication in tumorigenesis, tissue-specific dysregulation in cancer [14], and presence in human serum in an extremely stable form resistant to RNase digestion, harsh conditions, extended storage, and multiple freeze-thaw cycles [15], miRNAs have emerged as a novel source of blood-based reporters of cancer progression. Studies assessing serum or plasma miRNAs as biomarkers in a variety of cancers have largely focused on distinguishing cancer patients from control subjects [16,17]. While there is growing interest in evaluating the prognostic potential of circulating miRNAs [18-21], to the best of our knowledge, no study has specifically examined the association between serum-based miRNAs and recurrence risk in primary melanoma patients.

**Methods**

**Study population**

A total of 140 primary cutaneous melanoma patients who presented to New York University (NYU) Langone Medical Center for surgical resection of AJCC stage I-III disease were studied. Pre-treatment sera were collected at the time of initial diagnosis. A discovery cohort of 80 patients (discovery cohort) and an independent cohort of 50 patients (validation cohort) were used to construct prognostic models. Sera collected at the time of primary diagnosis and recurrence were available for a subset of patients (n = 17). All patients had histologically confirmed melanoma [22]. Relevant demographic and clinicopathological data were obtained from the prospectively maintained NYU Interdisciplinary Melanoma Cooperative Group (IMCG) database [22]. Both locoregional (stage III) and distant metastases (stage IV) were defined as recurrences. Additionally, an independent set of 10 melanoma patients had sera collected before and 7–14 days after surgical resection. The NYU Institutional Review Board approved the study and informed consent was obtained from all patients at the time of enrollment.

All serum samples were collected in 10-mL BD serum tubes, stored immediately at 4°C, and then centrifuged at 10°C for 10 minutes at 1,500 x g. The supernatant serum was then aliquoted into 1.5 mL cryovials and stored at –80°C until further use.

**miRNA extraction, quantitative reverse transcription-PCR (qRT-PCR) screening and individual evaluation**

Total RNA was extracted from sera using the Qiagen miRNeasy® Mini Kit using manufacturer’s instructions with minor modifications and eluted with 50μL of RNase-free water. Reverse transcription (RT) was performed using 8 μl RNA in 40 μl reactions using the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon, Denmark). cDNA was diluted 50x and amplified in 10 μl PCR reactions following manufacturer’s instructions by qPCR on a unique Pick & Mix discovery panel containing 355 miRNA assays and positive and negative controls. Negative controls excluding template from the RT reaction were performed and profiled like the samples. Amplification was performed in 384 well plates in a LightCycler® 480 Real-Time PCR System (Roche) and curves were analyzed using Roche LC software.

Notably, the qPCR platform (Exiqon) utilized has been reported to be the most sensitive and specific qPCR platform available when analyzing ultra low miRNA levels (200 copies or less) as found in serum and other biofluid samples [23]. The miRCURY platform has a very high degree of linearity (r² ≥ 0.9) across four log scales of miRNA copies for all assays, indicating good performance of the panel at very low miRNA concentrations. True sensitivity of the platform is maximized because of two features. First, cDNA synthesis is carried out using a universal approach that allows all miRNAs in a sample to be synthesized equally. Second, LNAs are incorporated into the PCR primers making the PCR assay performance independent of GC content, which can
otherwise affect the miRNAs ability to be efficiently amplified and accurately quantified.

Of the 355 miRNA assays, 170 miRNAs were included in analysis as they had Ct ≤ 40 and were detected with 5 Cts less than the no RT template included negative control in greater than two-thirds of patients. Expression data for 2 patients did not pass the quality control (QC) criteria and were not included in further analysis. Additionally, 1 patient had missing expression data for miR-199a-5p and was not included in analyses of models containing this miRNA.

A panel of 11 miRNAs (miR-15b, -23b, -30d, -33a, -103, -150, -199a-5p, -423-5p, -424, -425 and let-7d) identified as potential predictors of recurrence in multivariable models were selected for evaluation in the validation cohort using individual qRT-PCR assays. RT using 2 μl RNA in 10 μl reactions was performed in duplicate, amplified by qPCR and analyzed following the protocol described above.

Longitudinal evaluation of miRNA expression
In exploring the potential of serum miRNAs as markers of melanoma recurrence, we elected to use a targeted approach to select miRNAs for study in pre-/post-operative and pre-/post-recurrence samples. We included several of the miRNAs that we identified as having prognostic potential in our discovery phase and were further evaluated in the validation cohort (i.e. miR-103, -191, -423-5p, -425). We did not limit ourselves to using only those miRNAs included in the recurrence risk signature as markers of prognosis may not translate into markers of disease detection. Instead, we focused on miRNAs from our prioritized panel that had previously supported roles in cancer progression and/or diagnostic utility. For example, high levels of miR-103 are associated with metastasis and poor outcome in breast cancer patients and functionally, mir-103 confers migratory capacities in vitro [24]. Elevated expression of miR-191 promotes epithelial-to-mesenchymal transition in hepatocellular carcinoma [25]. miR-423-5p was identified as part of a 5-miRNA signature for gastric cancer diagnosis [26]. We also chose to include one miRNA, miR-425, whose functional relevance in cancer was previously unexplored to avoid eliminating potentially useful markers. Additionally, we selected miRNAs that have well supported roles in melanoma progression (i.e. miR-182, -221, -222) as demonstrated by tissue-based studies [27,28].

Total RNA was extracted using the miRVana Paris isolation system (Ambion, USA) following the manufacturer’s protocol with the addition of an acid/phenol/chloroform extraction in a final elute of 100 μl. RT was performed using 2.5 μl miRNA in a final volume of 10 μl following manufacturer’s instructions using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, USA). qRT-PCR was performed in triplicate on a MyiQ Single Color Real Time PCR detection system (Bio-Rad, USA), using 1.33 μl cDNA, 1 μl miRNA-specific TaqMan® primer and 1x Hotmaster Master mix containing Taq DNA polymerase (5 Prime, USA) and dNTP Mix (Promega, USA) in a final volume of 20 μl per reaction. The amplification protocol was: 95°C for 17 min, 40 cycles at 95°C for 15 sec followed by 60°C for 1 min.

Statistical methods
Using the discovery cohort (n = 80), miRNAs were first ranked by univariate association of expression level for each miRNA with recurrence-free survival (RFS) via Cox proportional hazards regression analysis with adjustment for tumor stage. Top-ranking miRNAs were used as candidates to be included in the multivariate Cox proportional hazards model. The 5 miRNA-signature was selected by minimizing Akaika’s information criterion (AIC) of the multivariate Cox proportional hazards model through stepwise selection [29,30]. The linear combination of model predictors weighted by regression coefficients was defined as the risk score. A cutoff of the risk score was chosen to separate patients into high and low recurrence risk groups [31]. Kaplan-Meier survival curves for the resulting groups were plotted, and log-rank test was used to compare the two curves. To test the classifier, regression coefficients of the Cox model were applied to the validation cohort (n = 50) to obtain a risk score, and the same cutoff was used to predict RFS in the validation cohort.

The identified miRNA signature set was also evaluated for its utility in predicting 3-year RFS by logistic regression model using recurred patients (n = 25) and non-recurred patients (n = 44) with ≥3 years follow-up from the discovery cohort as cases and controls, respectively [32]. An optimal risk score cutoff using the Youden Index of the Receiver Operating Characteristic (ROC) curve was chosen to classify patients into high and low risk groups. Kaplan-Meier survival curves and log-rank tests were used to compare the RFS distributions of the two groups. The logistic model was used to predict recurrence risk in the validation cohort of 20 recurred and 16 non-recurred patients with ≥3 years follow-up. The same risk score cutoff was used to classify patients.

As a subset analysis to demonstrate the utility of serum miRNAs beyond tumor stage, we built a logistic model using the panel of 11 prioritized miRNAs in all stage II patients and examined its ability to distinguish patients with and without recurrence by cross validation, and examined the RFS difference using Kaplan-Meier curves between the predicted high vs. low risk groups. Longitudinal changes in miRNA expression were assessed using two-sided Student’s t tests (p < 0.05). All statistical analyses were performed in R 2.12.0.

The reported results are based on Ct values that passed QC but without further normalization. To assess the
method for analysis, various ways of normalizing miRNA expression were explored (i.e. median normalization: shift Ct values on each panel by additive constants such that the medians of miRNA expression are the same across panels). The resulting candidate set of miRNAs identified were similar to those obtained when data were not normalized; moreover, selected classifiers worked well whether Ct values were normalized or not, indicating the robustness of the developed models.

**Results**

Clinical and pathologic characteristics of the 130 patients used in prognostic modeling are presented in Table 1. Recurrence status stratified by stage for patients in the discovery and validation cohorts is shown in Table 2. The median time of follow-up for survivors was 42.5 months (range, 17–237 months).

**Cox proportional hazards model identifies a miRNA signature with prognostic potential**

We screened serum samples of the discovery cohort using a qPCR platform of 355 miRNAs, of which data for 170 miRNAs were available for at least 67% samples. A multivariate Cox proportional hazards model for RFS was identified, which contains 5 miRNAs (miR-150, -15b, -199a-5p, -33a, -424) with adjustment for stage (Table 3). The linear combination of model predictors weighted by regression coefficients was defined as the risk score. Motivated by Satzger et al. [31], a cutoff was chosen to separate patients into high and low recurrence risk groups aimed at maximizing the log-rank statistic (sensitivity = 0.84, specificity = 0.76; high risk, n = 34, low risk, n = 46). Kaplan-Meier analysis revealed that the two groups have a significant separation in RFS (p = 0.0036, Figure 1A). The model was applied to predict recurrence risk in the validation cohort, and the same cutoff was used to separate patients into high and low recurrence risk groups (sensitivity = 0.84, specificity = 0.60; high risk n = 28, low risk n = 21). Kaplan-Meier analysis indicated that the resulting RFS distributions were again significantly different (p = 0.009, Figure 1B).

**Logistic regression analysis confirms prognostic potential of miRNA-based risk model for 3-year RFS**

The performance of the 5 miRNAs identified by Cox analysis was then evaluated by logistic regression analysis. In the discovery cohort, the addition of the 5-miRNA signature to a base risk model containing stage as a predictor improved the performance of the classifier, demonstrated by an increase in the area under the ROC curve (AUC) from AUC = 0.77 (95% CI, 0.66–0.89) of stage alone to AUC = 0.84 (95% CI, 0.73–0.94) with the 5-miRNA signature. Using a cutoff to separate the discovery cohort into high and low recurrence risk groups (sensitivity = 84%, specificity = 64%), the two groups had significant separation of RFS (p < 0.0001, Figure 2A). The model was applied to predict recurrence in the validation cohort, and the same cutoff was used to define high and low recurrence risk groups (sensitivity = 95%, specificity = 41%). Performance of the classifier was maintained, with significant separation of RFS (p = 0.033, Figure 2B).

**A signature of candidate miRNAs as predictors of recurrence in stage II melanoma supports that miRNA signatures might have prognostic utility beyond tumor stage**

Recurrence status among all stage II patients was relatively balanced, with 19 recurred and 20 non-recurred after

---

**Table 1 Baseline characteristics of melanoma patients**

| Variable               | Melanoma patients (n = 140) | N (%) |
|------------------------|-----------------------------|-------|
| Age at diagnosis, years|                             | 59    |
| Gender                 |                             |       |
| Male                   |                             | 82 (59)|
| Female                 |                             | 58 (41)|
| Thickness, mm          |                             | 2 (0.27-28)|
| Ulceration             |                             |       |
| Present                |                             | 49 (35)|
| Absent                 |                             | 91 (65)|
| Mitosis                |                             |       |
| Absent                 |                             | 27 (19)|
| Present                |                             | 97 (69)|
| Unclassified           |                             | 16 (11)|
| Histological type      |                             |       |
| Superficial Spreading  |                             | 54 (39)|
| Nodular                |                             | 44 (31)|
| Other a                |                             | 25 (18)|
| Unclassified           |                             | 17 (12)|

**NOTE.** Percentages may not sum to 100% as a result of rounding

*Other includes acral lentiginous melanoma, desmoplastic melanoma and lentigo maligna.

**Table 2 Recurrence status of melanoma patients stratified by stage**

| Stage | Discovery Cohort | Validation Cohort |
|-------|------------------|-------------------|
|       | No recurrence    | Recurrence        | No recurrence    | Recurrence        |
| I     | 34               | 5                 | 10               | 0                 |
| II    | 13               | 7                 | 16               | 12                |
| IIIa  | 8                | 13                | 4                | 8                 |
| Totals| 55               | 25                | 30               | 20                |

*Includes 1 patient diagnosed with stage III melanoma, but did not have blood drawn until time of recurrence with stage IV disease.*
≥3 years follow up. Thus, this group was selected for subgroup analyses as proof-of-principle that serum-based miRNAs have prognostic potential beyond stage. Stage II patients pose a particularly difficult clinical challenge. Though still localized melanoma, stage II patients have significantly lower survival rates than stage I patients, with 5-year survival rates from 53% to 82% compared to >90%, respectively [33]. In our cohort of stage II patients, a logistic risk model with thickness alone was able to distinguish recurred from non-recurred patients with an AUC = 0.75 (p = 0.06). With the addition of 3 of the miRNAs prioritized for further evaluation (miR-423-5p, -424, -199a-5p), the performance of the classifier improved (AUC = 0.89, Figure 3A), and 2 of the miRNAs were significant predictors of recurrence in the model (miR-423-5p: Odds Ratio (OR), 0.038; 95% CI, 0.0031-0.46; p = 0.008; miR-424: OR, 3.64; 95% CI, 1.19-11.1; p = 0.018). Four-fold cross validation demonstrated an AUC = 0.81. Using Youden’s index of ROC curve as a cutoff to separate patients into high and low recurrence risk groups (sensitivity = 94%, specificity = 75%), the two groups had significant separation of RFS (p < 0.0001, Figure 3B).

miRNAs show potential in monitoring for melanoma recurrence

To evaluate the clinical feasibility of using circulating miRNAs in post-resection surveillance for recurrence, we first measured the expression of 7 miRNAs, selected from our prioritized panel of 11 miRNAs based on previously supported roles in cancer progression and/or diagnostic utility and from tissue-based miRNA studies supporting an association with melanoma progression [27,28], in 10 matched serum samples collected pre- and post-resection of primary melanoma. Mean expression levels of all 7 miRNAs were reduced after operation, but only the difference in mean expression of miR-221, -222 and -423-5p reached statistical significance (p < 0.05). Next, we measured the expression of these miRNAs in pre- and post-recurrence serum samples from a subset of the discovery cohort (n = 17). Serum levels of all 7 miRNAs were increased, with mean expression of 2 miRNAs (miR-103 and -221) showing statistically significant post-recurrence elevation (p < 0.025, Figure 4).

Discussion

We present the first study demonstrating the potential prognostic value of serum miRNAs in melanoma. Specifically, we provide evidence that serum miRNAs show promise as biomarkers for improved identification of high-risk melanoma patients at the time of primary diagnosis. By doing so, we introduce biological subclassifiers that could add to the utility of clinical prognostic indicators and help account for latent heterogeneity in melanoma. This is increasingly important as better adjuvant
therapies are developed, as it would enable clinicians to target those likely to recur for aggressive treatment.

We identify miRNAs that are potential markers of disease progression in melanoma patients. In other malignancies, such as colon, liver, testicular, prostate, and ovarian cancers, serum tumor markers have become part of the standard of care in surveillance for recurrence, at times used in lieu of periodic imaging in asymptomatic patients [34]. In melanoma, however, there are no widely available circulating markers that can facilitate early detection of relapse. Here, we show support for an association between serum miRNAs and tumor burden, a feature that if further developed, could be exploited by incorporation of serum miRNAs assays in routine surveillance for melanoma recurrence.

While there are several tissue-based and in vitro studies of miRNA dysregulation in melanoma [28,32,35-39], little is known about the “source” of serum miRNAs [19,21]. There is speculation that the source is not limited to the tumor and can include miRNAs shed from the tumor microenvironment or from circulating immune cells that also reflect the myriad of events involved in the initiation and development of malignancy. This suggests that, though tissue-based analyses are useful for
understanding cancer biology, there is a complimentary role for studying circulating miRNAs as an independent source of biologically and clinically relevant information.

Growing interest in circulating miRNAs as biomarkers has resulted in several studies exploring their potential in solid tumors. However, the emphasis has been placed on elucidating the diagnostic capabilities of blood-based miRNAs [16,17]. In melanoma, one group reported on serum miR-221 levels and demonstrated a correlation with tumor thickness [40]. The second used array screening to identify unique miRNA expression profiles in peripheral blood cells of melanoma patients compared to healthy controls [35], which requires analysis of fresh blood specimens, and limits the practicality of the approach.

While we are the first to identify the prognostic relevance in melanoma of three of the miRNAs included in the recurrence risk signature (miR-199a-5p, -33a, -424), the biological function of all the identified miRNAs have begun to be elucidated in tissue and in vitro studies. miR-150 directly targets MUC4 in pancreatic cancer cells, an aberrantly overexpressed transmembrane mucin promoting growth, invasion and metastasis. miR-150 overexpression inhibits growth, clonogenicity, migration and invasion, and enhances intracellular adhesion in pancreatic cancer cells [41]. Clinically, miR-150 was elevated in melanoma tissues of patients with longer post-recurrence survival [39], also supporting a tumor suppressor role. Conflicting data exist regarding a pro-proliferative effect of ectopic expression of miR-150 in gastric cancer both in vitro and in vivo, at least in part due to repression of the tumor suppressor EGR2, resulting in translational arrest [42]. Our findings are in line with an oncogenic role for miR-150, with higher circulating expression of miR-150 in patients with a high recurrence risk. However, our findings can also be due to the possibility that serum miRNAs reflect the systemic immune response as miR-150 has a role in the modulation of the T-cell development. Specifically, via modulation of NOTCH3, overexpression of miR-150 has adverse effects on T-cell proliferation and survival, resulting in decreased antitumor immunity and subsequent progression [43].

In our model, patients with high recurrence risk had lower levels of miR-15b, similar to findings in a recent study showing an association between reduced miR-15b expression, chemotherapeutic resistance and poor prognosis in patients with tongue squamous cell carcinoma [44]. The same study identified BIM1 as a functional
the utility of current prognostic factors in predictive models of melanoma recurrence. This would allow for the evolving paradigm shift towards a molecular characterization of melanoma to improve prognostic accuracy, detect recurrence, and better guide management decisions has largely been devoid of blood-based mRNA studies. We show that serum-based miRNAs demonstrate hallmarks of useful tumor markers, namely easy detection in accessible samples and promising clinical utility and applicability in melanoma. We demonstrate support for the use of serum miRNAs as clinically useful non-invasive biomarkers that could potentially enhance the utility of current prognostic factors in predictive models of melanoma recurrence. This would allow for
improved stratification of a heterogeneous cancer that could be influential in clinical decision-making. Specifically, the development of serum miRNAs into clinical assays can refine criteria for more extensive staging procedures, such as sentinel lymph node biopsy, and for inclusion in clinical trials. Moreover, the potential exists for serum miRNAs to not only guide follow-up recommendations and allow for better allocation of resources, but also to improve the power of the current arsenal of imaging and laboratory tests used in routine surveillance. Future large prospective studies focusing on the identified serum-based miRNAs stand to have a potentially large clinical impact in aiding the early identification of primary melanoma patients with high risk for recurrence and in the timely detection of disease relapse.

Abbreviations
miRNAs: microRNAs; qRT-PCR: Quantitative reverse transcription-PCR; RFS: Recurrence-free survival; AIECC: American Joint Committee on Cancer; NYU: New York University; IMCG: Interdisciplinary Melanoma Cooperative Group; RT: Reverse transcription; QC: Quality control; AIC: Akaike’s Information Criterion; ROC: Receiver Operating Characteristic; AUC: Area under the curve; OR: Odds ratio; CI: Confidence interval.

Competing interests
MWT and AB are currently paid employees of Exiqon A/S, Denmark. JUF was a paid employee of Exiqon A/S, Denmark at the time the research was conducted.

Authors’ contributions
EBF participated in study design, coordination, data collection, data analysis, drafting, revising and finalizing of the manuscript. SS performed the statistical design and analysis under the guidance of YS and participated in the writing of the manuscript. EV participated in study design and data collection. JUF participated in study design and data collection. MWT participated in study design and data collection. MWM participated in data analysis and manuscript drafting/finalization. RSB recruited patients for the study, provided input on study design, and helped to draft the manuscript. AB provided guidance in study design, data collection, and writing of the manuscript. YS was the principal statistician for the study, providing guidance on statistical design and data analysis. IO served as the finalization. AB provided guidance in study design, data collection, and helping to draft the manuscript. EH helped to draft the manuscript. ACP recruited patients for the study, provided input on study design, and helped to draft the manuscript. RLS recruited patients for the study, provided input on study design, and helped to draft the manuscript. RL received the statistical design and analysis of the manuscript. EV participated in study design and data analysis and manuscript drafting/finalization. RSB recruited patients for the study, provided input on study design, and participated in the writing of the manuscript. EV participated in study design and data collection. JUF participated in study design and data collection. MWT participated in study design and data collection. MWM participated in data analysis and manuscript drafting/finalization. RSB recruited patients for the study, provided input on study design, and helped to draft the manuscript. RLS recruited patients for the study, provided input on study design, and helped to draft the manuscript. EBF participated in the conceptual study design, provided guidance regarding interpretation of results, and helped with manuscript preparation and finalization. AB provided guidance in study design, data collection, and writing of the manuscript. YS was the principal statistician for the study, providing guidance on statistical design and data analysis. IO served as the principal investigator for the project, overseeing the study design, analysis of data, interpretation of results, and writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Daniel Lackaye and Holly Greenwald for the management of the clinical information of the IMCG patients. This work was supported by the Nih funded Clinical and Translational Science Institute Award (1UL1RR028983, IO and EBF), the NYU Cancer Institute Center Support Grant (SP30CA16087), and the Marc Jacobs Campaign to support the Interdisciplinary Melanoma Cooperative Group.

Author details
1. Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, NY, USA. 2. Department of Pathology, New York University School of Medicine, New York, NY, USA. 3. Division of Biostatistics, New York University School of Medicine, New York, NY, USA. 4. The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York NY, USA. 5. Exiqon A/S, 2950, Vedbaek, Denmark. 6. Department of Medicine, New York University School of Medicine, New York, NY, USA. 7. Department of Pathology, New York University School of Medicine, New York, NY, USA.

Received: 26 April 2012 Accepted: 18 July 2012

References
1. SEER Cancer Statistics Review, 1975–2008. [Internet] (http://seer.cancer.gov/csr/1975_2008/)
2. Tao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998–1012.
3. Garbe C: A rational approach to the follow-up of melanoma patients. Recent Results Cancer Res 2002, 160:205–215.
4. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Genneryael JD, Houghton A, Kirkwood JM, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3653–3668.
5. Leiter U, Buettner PG, Eigentler TK, Forsschner A, Meier F, Garbe C: Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 2010, 20:240–246.
6. Grange F, Vité F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalarç S, Truchetet F, Michel C, Baratard ML, et al: Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol 2008, 144:629–636.
7. Hofmann U, Sätzlak M, Rittgen W, Jung EG, Schadendorf D: Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002, 87:151–157.
8. Bant RC Jr, Radón P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennis RG, Somerfield MR: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865–1878.
9. Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL: Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 2004, 64:8767–8772.
10. Deichmann M, Benner A, Bock M, Jäckel A, Ulhl K, Waldmann V, Nähler H: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999, 17:1891–1896.
11. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM: Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009, 27:38–44.
12. Garbe C, Paul A, Kohler-Spalth H, Elwanger U, Stroebel W, Schwarz M, Schlagenhoff B, Meier F, Schmittk B, Blaheta HJ, et al: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21:520–529.
13. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 110:225–236.
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 2005, 435:834–838.
15. Mitchell PS, Parkin RK, Krohn EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513–10518.
16. Cortez MA, Bueno-Ramos C, Fardin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids: mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467–477.
17. Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703–711.
18. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boulton J, Wainscoat JS, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672–675.
bimarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745.

20. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1723–1726.

21. Boeri M, Veni C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713–3718.

22. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, Goldberg JD, Hernandez E, Manga P, Kriegsgaard M, et al: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009, 1:135–43.

23. Jensen SG, Lamy P, Rasmussen MH, Ostenfeld MS, Dyskjoet J, Omtvist TF, Andersen CL: Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435.

24. Martello G, Rosato A, Ferrari F, Marfini A, Cordemoni M, Dupont S, Erazo E, Guzzardo V, Rondina M, Spence T, et al: A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195–1207.

25. He Y, Cui Y, Wang W, Gu J, Guo S, Ma K, Luo X: Hypomethylation of the hsa-mir-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 2011, 13:841–853.

26. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011, 47:784–791.

27. Segura MT, Hanniford D, Menendez S, Reavei L, ZoV Alvarez-Diaz S, Zakrzewski J, Blochien E, Rose A, Bogunic D, et al: Ablaterant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009, 106:18141–18149.

28. Felicetti F, Ernico MC, Segnalini P, Mattia G, Care A: MicroRNA-221 and –222 pathway controls melanoma progression. Expert Rev Anticancer Ther 2008, 8:1759–1765.

29. Klein J, Moechberg G: Survival Analysis: Techniques for Censored and Truncated Data. 1st edition. New York: Springer-Verlag; 1997.

30. Wang Y, Chen H, Li R, Duan N, Lewis-Fernandez R: Prediction-Based Structured Variable Selection through the Receiver Operating Characteristic Curves. Biometrics 2011, 67:896–905.

31. Satzger I, Matern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmacher R: MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. J Cancer Research 2010, 126:2553–2562.

32. Poo-Hwu WJ, Arhyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC: The 1st edition. New York: Springer-Verlag; 1997.

33. Balch CM, Gershenwald JE, Soong SJ, Thompson JP, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199–6206.

34. Duffy MJ: Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007, 18:175–184.

35. Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, Lenhof HP, Guzmardo J, Rondina M, Spruce T, et al: Mir-33 regulates cell proliferation and cell cycle progression. Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, et al: MiR-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012, 11:.

36. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Ghosh GP, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Ghosh GP, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Ghosh G: MicroRNA-221 and –222 expression predict survival of non-small-cell lung cancer patients with malignant melanoma. Eur J Intern Med 2011, 22:345–350.

37. Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO: One of the two miRNAs hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 2011, 13:841–853.

38. Hu Z, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, et al: miR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 2010, 392:340–345.

39. Ghisii M, Coradin A, Basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, Bonanno L, Guffanti A, et al: Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-15b. Blood 2011, 117:7053–7062.

40. Sony L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, et al: MiR-200b and miR-15b regulate chemotheray-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2011, 30:432–445.

41. Xiao L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong J, Liu J, Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. int J Cancer 2008, 123:372–379.

42. Li Z, Gu X, Fang Y, Xiang J, Chen Z: microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 2012, 3:346–350.

43. Sakurai K, Furukawa C, Haraguchi T, Inada K, Shigoma K, Tagawa T, Fujita S, Ueno Y, Ogata A, Ito M, et al: MicroRNAs miR-199a-5p and -3p target the Bcrp subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 2011, 71:1680–1699.

44. Thomas M, Lange-Gruenewell K, Weirnach U, Gutsch D, Aigner A, Grunewell W, Aigner A, Hartmann RK: The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012, 31:918–928.

45. Cirea-Saltanit D, Pauta M, Allen RM, Salerno AG, Ramirez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, et al: MiR-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012, 11:.

46. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Ghosh GP, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Ghosh G: MicroRNA-221 and –222 expression predict survival of non-small-cell lung cancer patients with malignant melanoma. Eur J Intern Med 2011, 22:345–350.

47. Rosa A, Ballarino M, Sorrentino A, Schandelier O, De Angelis FG, Marchioni M, Masella B, Guarini A, Peschle C, Bozzoni I: The interplay between the master transcription factor PU1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci U S A 2007, 104:19849–19854.

48. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23:7332–7341.